Where our team of editors discuss what they think about the current NGP US Issues.
Franz Humer, a lawyer by training, is CEO of F. Hoffmann-La Roche Ltd – a company whose strategy is to use innovative scientific breakthroughs to shape the future of medicine.
The pharmaceutical business – once the envy of fellow industries for its year-on-year surging profits – has suddenly found itself staring at a crisis.
Martin Terberger, Head of Unit, Pharmaceuticals, Directorate General, Enterprise and Industry outlines the European Commission’s view on pharma moving forward.
In their quest to be innovative, pharmaceutical and biotechnological companies are applying their own strategies in response to the growing demands for improvement, creative ideas, breakthrough technologies and new medicines.
What does Europe have to gain from an innovative, research-based pharmaceutical industry? And what challenges is the industry facing? By Brian Ager, Director General of the European Federation of Pharmaceutical Industries and Associations EFPIA.